NO20016035D0 - Anvendelse av antistoff mot CD20 ved behandling av avstötning av implantanter - Google Patents

Anvendelse av antistoff mot CD20 ved behandling av avstötning av implantanter

Info

Publication number
NO20016035D0
NO20016035D0 NO20016035A NO20016035A NO20016035D0 NO 20016035 D0 NO20016035 D0 NO 20016035D0 NO 20016035 A NO20016035 A NO 20016035A NO 20016035 A NO20016035 A NO 20016035A NO 20016035 D0 NO20016035 D0 NO 20016035D0
Authority
NO
Norway
Prior art keywords
implants
rejection
antibody
treatment
Prior art date
Application number
NO20016035A
Other languages
English (en)
Other versions
NO20016035L (no
Inventor
Josee Golay
Martino Introna
Alessandro Rambaldi
Andrea Biondi
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Publication of NO20016035D0 publication Critical patent/NO20016035D0/no
Publication of NO20016035L publication Critical patent/NO20016035L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20016035A 1999-06-11 2001-12-10 Anvendelse av antistoff mot CD20 ved behandling av avstötning av implantanter NO20016035L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001299A ITMI991299A1 (it) 1999-06-11 1999-06-11 Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
PCT/EP2000/005212 WO2000076542A1 (en) 1999-06-11 2000-06-07 Use of antibodies against cd20 for the treatment of the graft versus host disease

Publications (2)

Publication Number Publication Date
NO20016035D0 true NO20016035D0 (no) 2001-12-10
NO20016035L NO20016035L (no) 2002-02-11

Family

ID=11383150

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016035A NO20016035L (no) 1999-06-11 2001-12-10 Anvendelse av antistoff mot CD20 ved behandling av avstötning av implantanter

Country Status (26)

Country Link
US (1) US20070014785A1 (no)
EP (1) EP1185299B1 (no)
JP (1) JP2003501482A (no)
KR (1) KR20020026455A (no)
CN (1) CN1253208C (no)
AU (1) AU774206B2 (no)
BG (1) BG106193A (no)
CA (1) CA2376288A1 (no)
CZ (1) CZ20014450A3 (no)
DE (1) DE60033030T2 (no)
DK (1) DK1185299T3 (no)
EE (1) EE200100667A (no)
ES (1) ES2278616T3 (no)
HK (1) HK1043549B (no)
HU (1) HUP0201600A3 (no)
IL (1) IL146934A0 (no)
IS (1) IS6195A (no)
IT (1) ITMI991299A1 (no)
NO (1) NO20016035L (no)
NZ (1) NZ515992A (no)
PL (1) PL352860A1 (no)
PT (1) PT1185299E (no)
SK (1) SK18132001A3 (no)
TR (1) TR200103581T2 (no)
WO (1) WO2000076542A1 (no)
ZA (1) ZA200110004B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP3263596A1 (en) * 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
CA2519870A1 (en) 2003-04-09 2004-10-28 Genentech, Inc. Use of rituximab intravenous compositions to treat rheumatoid arthritis
JP5416338B2 (ja) 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
CA2526402A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
US8530187B2 (en) * 2004-03-22 2013-09-10 The Ohio State University Research Foundation Methods for transfecting natural killer cells
CN106075435A (zh) 2004-06-04 2016-11-09 健泰科生物技术公司 用于治疗多发性硬化的方法
BR122018016031B8 (pt) 2004-08-04 2021-07-27 Applied Molecular Evolution Inc processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
ATE460672T1 (de) 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
CN101267836A (zh) 2005-07-25 2008-09-17 特鲁比昂药品公司 单剂量cd20特异性结合分子的用途
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
CN101008291B (zh) * 2006-01-26 2010-05-12 金海产品有限公司 用于水池清洁机的密封盒装置
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
KR101432191B1 (ko) 2007-06-22 2014-08-20 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 이식편대숙주 질환의 검출 또는 치료 방법
SG10202005450PA (en) 2007-07-09 2020-07-29 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
ES2527297T3 (es) 2007-07-31 2015-01-22 Regeneron Pharmaceuticals, Inc. Anticuerpos humanos para CD20 humano y método para utilizar los mismos
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
RU2639288C2 (ru) 2009-08-11 2017-12-20 Дженентек, Инк. Получение белков в культуральных средах без глутамина
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3221359B1 (en) 2014-11-17 2020-05-27 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
CN114031689A (zh) 2015-10-02 2022-02-11 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CA3044526A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US11590223B2 (en) 2018-08-31 2023-02-28 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP2000511539A (ja) * 1996-05-31 2000-09-05 ジェネティック・セラピー・インコーポレイテッド 負の選択マーカーをコード化するポリヌクレオチドを含むｔ細胞による対宿主性移植片病の予防
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses

Also Published As

Publication number Publication date
EP1185299A1 (en) 2002-03-13
CN1253208C (zh) 2006-04-26
SK18132001A3 (sk) 2002-05-09
IS6195A (is) 2001-12-10
HUP0201600A2 (en) 2002-08-28
WO2000076542A1 (en) 2000-12-21
ZA200110004B (en) 2003-02-26
AU5530300A (en) 2001-01-02
NZ515992A (en) 2004-01-30
EP1185299B1 (en) 2007-01-17
ITMI991299A1 (it) 2000-12-11
IL146934A0 (en) 2002-08-14
BG106193A (bg) 2002-08-30
US20070014785A1 (en) 2007-01-18
CZ20014450A3 (cs) 2002-04-17
CN1355712A (zh) 2002-06-26
AU774206B2 (en) 2004-06-17
PL352860A1 (en) 2003-09-08
HUP0201600A3 (en) 2005-04-28
DK1185299T3 (da) 2007-05-21
EE200100667A (et) 2003-02-17
ITMI991299A0 (it) 1999-06-11
JP2003501482A (ja) 2003-01-14
ES2278616T3 (es) 2007-08-16
DE60033030D1 (de) 2007-03-08
NO20016035L (no) 2002-02-11
PT1185299E (pt) 2007-03-30
KR20020026455A (ko) 2002-04-10
HK1043549A1 (en) 2002-09-20
HK1043549B (zh) 2006-09-01
TR200103581T2 (tr) 2002-08-21
DE60033030T2 (de) 2007-05-31
CA2376288A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
NO20016035D0 (no) Anvendelse av antistoff mot CD20 ved behandling av avstötning av implantanter
NO20020639L (no) Anvendelse av anti-CD20-antistoff ved behandling av non-Hodgkins-lymfom med involvering av benmarg
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO20031218L (no) Kombinasjonsterapi for behandling av autoimmunsykdommer ved anvendelse av B-cellereduserende immunregulerende antistoff kombinasjon
FR15C0070I2 (fr) Composes heteroaromatiques azotes pour le traitement des maladies de cancer
PT1028954E (pt) Imidazoles substituidos uteis no tratamento de doencas inflamatorias
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
DE60112340D1 (de) Absorbierende Matte zur Behandlung von Ausscheidungen
NO20024682L (no) Kombinert anvendelse av anti-cytokin-antistoff eller antagonister og anti-CD20 ved behandling av B-celle-lymfom
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
ATE357459T1 (de) Antikörper gegen mensliches il-12
NO20041802L (no) Antistoffer mot human vevsfaktor
DE60022826D1 (de) Absorbierender Wegwerfartikel zur Behandlung von Fäkalien
ID26300A (id) Benda penyerap sekali pakai
DK1176964T3 (da) Brug af ET743 til behandling af cancer
NO20021301D0 (no) Anvendelse av CSAIDS ved rinovirusinfeksjon
DE60136477D1 (de) Retinoide zur behandlung von emphysem
EE200300473A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
EE200300474A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
NO20015864L (no) Blokkerende monoklonalt antistoff mot VLA-1 samt anvendelse derav ved behandling av inflammatoriske lidelser
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
PT1152756E (pt) Derivados de anticonvulsivo uteis no tratamento do autismo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application